Table 3 Number of observed second tumours in a cohort of women with breast cancer in Turin (Italy), AJ-IR
From: Multiple primary tumours: incidence estimation in the presence of competing risks
Cancer Site | Observed cases | AJ-IRstand (95% C.L.) |
|---|---|---|
Mouth Pharynx | 7 | 0.80 (0.39–1.47) |
Oesophagus | 5 | 2.38 (0.92–5.01) |
Stomach | 29 | 1.38 (0.97–1.93) |
Colon-Rectum | 66 | 0.87 (0.69–1.10) |
Liver | 7 | 0.61 (0.23–1.30) |
Gallbladder | 8 | 0.78 (0.38–1.40) |
Pancreas | 20 | 1.39 (0.89–2.07) |
Lung | 24 | 0.80 (0.54–1.15) |
Melanoma | 14 | 1.15 (0.65–1.88) |
Cervix uteri | 9 | 0.68 (0.34–1.22) |
Corpus uteri | 54 | 1.91 (1.47–2.44) |
Ovary | 24 | 1.12 (0.74–1.64) |
Bladder | 14 | 0.74 (0.42–1.21) |
Brain & NS | 4 | 0.56 (0.18–1.31) |
Thyroid | 11 | 1.00 (0.46–1.89) |
NHL | 21 | 1.32 (0.85–1.94) |
Leukaemias | 9 | 0.81 (0.39–1.49) |
Other & unspecified | 27 | 0.48 (0.33–0.68) |
Total (breast and skin excluded) | 353 | 0.99 (0.91–1.10) |